Balyasny Asset Management
IRMD icon

Balyasny Asset Management’s iRadimed IRMD Stock Holding History

Balyasny Asset Management’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,498
Closed -$632K – 3194
2025
Q4 		$632K Buy
+6,498
New +$557K ﹤0.01% 2415

Other funds holding IRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's IRMD Position: Q1 2026 in Review

Balyasny Asset Management sold out of iRadimed (IRMD) in Q1 2026, closing a stake of 6,498 shares — an estimated $632K sold.

Balyasny Asset Management first reported a position in IRMD in Q4 2025 and held it in 1 quarter. The position peaked at $632K in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • Balyasny Asset Management reported no remaining iRadimed position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 6,498 iRadimed shares in Q1 2026, an estimated $632K.
  • Balyasny Asset Management first reported a position in iRadimed in Q4 2025 and held it in 1 quarter.
  • Balyasny Asset Management's iRadimed position peaked at $632K in Q4 2025.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.